How much funding has Lyell Immunopharma raised?

Lyell Immunopharma has raised $884.0M in total funding, most recently a Venture Round.

Who are Lyell Immunopharma's investors?

Lyell Immunopharma's investors include GV, ARCH Venture Partners, Foresite Capital, GSK, F-Prime Capital, Bain Capital Life Sciences.

When was Lyell Immunopharma founded?

Lyell Immunopharma was founded in 2018.

Where is Lyell Immunopharma headquartered?

Lyell Immunopharma is headquartered in South San Francisco, California, United States.

What industry is Lyell Immunopharma in?

Lyell Immunopharma operates in Biotech, Healthcare, Life Sciences, Therapeutics.

How many employees does Lyell Immunopharma have?

Lyell Immunopharma has 201-500 employees.

Lyell Immunopharma

formerly LyellIPO

Next-Generation CAR-T Cell Therapies for Cancer | Lyell

Public · South San Francisco, United States · Founded 2018 · $884.0M raised

Headquarters: South San Francisco, California
Employees: 201–500
Founded: 2018
Business Model: B2B
Website: lyell.com

Total Funding: $884.0M
Last Round: $50.0M Venture RoundJul 2025
Rounds: 6
Type: Public

About

Lyell Immunopharma is a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. Founded in 2018 and headquartered in South San Francisco, Lyell combines proprietary genetic and epigenetic T-cell reprogramming technologies with an in-house manufacturing facility (LyFE Manufacturing Center) to create potent, durable cell therapies designed to deliver lasting remissions with a single treatment.

Summary

Lyell Immunopharma is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $884.0M in total across 6 rounds, most recently a $50.0M Venture Round round in Jul 2025. Investors include GV, ARCH Venture Partners and Foresite Capital.